Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CBX7 | O95931 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.37 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.37 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623300 | 0.92 | SMN1; SMN2 (0.38) | TLR7CYP3A4CYP2C19CBX7RECQL | |
| SCHEMBL13623302 | 0.86 | TLR7 (0.38) | TLR7CYP3A4CYP2C19NPY1RAKT1 | |
| SCHEMBL4365344 | 0.82 | BCL6 (0.38) | TLR7CYP3A4CYP2C19AKT1AURKA | |
| SCHEMBL13623299 | 0.76 | BCL6 (0.37) | TLR7CBX7RECQLSMN1; SMN2CDYL2 | |
| SCHEMBL4359430 | 0.76 | NPC1 (0.36) | CYP3A4CYP2C19CBX7RECQLSMN1; SMN2 | |
| SCHEMBL13622713 | 0.74 | AURKA (0.48) | TLR7CYP3A4CYP2C19NPY1RAURKA | |
| SCHEMBL13670174 | 0.74 | AURKA (0.43) | TLR7CYP3A4CYP2C19NPY1RAURKA | |
| SCHEMBL13622510 | 0.74 | AURKA (0.43) | TLR7CYP3A4CYP2C19NPY1RAURKA | |
| SCHEMBL7156537 | 0.73 | MGLL (0.52) | TLR7CYP3A4CYP2C19RECQLSMN1; SMN2 | |
| SCHEMBL13669878 | 0.72 | NOX4 (0.45) | TLR7CYP3A4CYP2C19SMN1; SMN2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | TLR7 1054/4885CYP3A4 3025/4885CYP2C19 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.